Our Story

Tessa Therapeutics is founded on over three decades of research and development by our Scientific Co-Founder, Dr. Malcolm K Brenner, and his team at Baylor College of Medicine. Their research has shown that the body’s anti-viral immune response can be harnessed as a potent therapy for cancer treatment.

Learn More

Our Science

Our core platform technology uses a specific subset of immune cells known as Virus-Specific T cells (VSTs) which have shown early efficacy and strong safety profiles against solid tumors in clinical trials. We employ our understanding of the body’s anti-viral immune response to rationally design the next generation of cancer treatments.

Learn More

Our Pipeline

We have an advanced clinical pipeline of autologous and allogeneic therapies that combine VSTs with other immune-oncology approaches to target multiple tumor indications.

Learn More

Our Operations

We have successfully delivered cell therapies to patients in 30 clinical sites across Asia and North America, enabled by a global vein-to-vein operations and strong clinical trial network.

Learn More
null

Our Story

null

Our Science

null

Our Pipeline

null

Our Operations

Feature News

Tessa at a Glance

200+ employees

Learn More >>

5 Pipeline Assets

Learn More >>

Global Operations & Clinical Trial Network

Learn More >>

6 Strategic Partnerships

Learn More >>

Process Development Facility

Learn More >>

Upcoming cGMP Manufacturing Facility

Learn More >>

Tessa on Twitter

2 weeks ago
Dr Ramy Ibrahim, CMO @parkerici discusses some of the cellular #immunotherapy breakthroughs we can anticipate this decade in this interview with our CSO, Dr John Connolly
@hotirishmonkey: https://t.co/0oe9JLMJSl #celltherapy #solvecancer #bioinformatics https://t.co/J3bExyFFuD
1 month ago
We are excited to announce plans to open a 90,000 sq. ft. #celltherapy manufacturing facility in Singapore in 2020. The new facility will enable us to deliver our cell therapies faster and more reliably, to thousands of cancer patients annually worldwide. https://t.co/lcM3ExrGV0

Tessa’s Media Channel

In this latest interview, Dr Jonathan Maltzman discusses the potential of harnessing Regulatory T Cells in cellular immunotherapy and augmenting them to fight cancer and other viral illnesses.